GO
Loading...

AstraZeneca PLC

More

  • Jan 21- Amarin Corp Plc's shares fell more than 26 percent after U.S. health regulators rejected a preset testing process that was critical to the company seeking broader use of its blood fat-lowering drug. Analysts are skeptical of Amarin's ability to run a profitable business without the new indication of its only approved drug, Vascepa.

  • *Analysts had forecast annual sales of $407 mln by 2017. ZURICH, Jan 21- An experimental Roche drug designed to treat the "negative symptoms" of schizophrenia failed to meet its main goal in two late-stage studies, dealing a blow to the Swiss drugmaker's research hopes in the risky area of brain science.

  • *FTSEurofirst 300 ends up 0.2 pct at 1,326.37 points. *ESTOXX 50 closes up 0.2 pct at 3,119.53 points. LONDON, Jan 14- European shares edged higher on Tuesday, buoyed by gains in major pharmaceutical stocks and by a rebound in U.S. equities after U.S.

  • Prospect of weak earnings dents European shares Tuesday, 14 Jan 2014 | 10:33 AM ET

    U.S. stock markets and Germany's benchmark DAX equity index have hit record highs, but some investors are concerned that further gains will be limited until corporate earnings start to improve.

  • *Shares in AstraZeneca rise 2 percent. LONDON, Jan 14- AstraZeneca expects to return to growth faster than analysts currently predict after a wave of drug patent expiries, with 2017 revenue likely to be broadly in line with the 2013 level.

  • AstraZeneca sees 2017 revenue in line with 2013 level Tuesday, 14 Jan 2014 | 2:15 AM ET

    LONDON, Jan 14- AstraZeneca said on Tuesday it expected to return to growth after a wave of drug patent expiries earlier than analysts currently forecast, with 2017 revenue likely to be broadly in line with the 2013 level.

  • UPDATE 2-FDA approves AstraZeneca type 2 diabetes drug Wednesday, 8 Jan 2014 | 1:22 PM ET

    Jan 8- U.S. health regulators on Wednesday approved an AstraZeneca drug from a new class of medicines to treat type 2 diabetes after previously rejecting it over safety concerns. The medicine was co-developed by Bristol-Myers Squibb Co and AstraZeneca.

  • Midday movers: Monsanto, Macy's, MetLife & More Wednesday, 8 Jan 2014 | 12:48 PM ET

    Some of Wednesday's midday movers:

  • *Record 3.2 bln stg deal for BAE Systems. *AstraZeneca, Carillion, Bentley also come to market. The market set its record for risks hived off by schemes this year with its biggest deal to date, of 3.2 billion pounds from BAE Systems, along with others from AstraZeneca, Bentley and Carillion.

  • *Record 3.2 bln stg deal for BAE Systems. *AstraZeneca, Carillion, Bentley also come to market. The market set its record for risks hived off by schemes this year with its biggest deal to date, of 3.2 billion pounds from BAE Systems, along with others from AstraZeneca, Bentley and Carillion.

  • WASHINGTON, Dec 19- The drug company AstraZeneca PLC lost a bid on Thursday to defend its widely used heartburn drug Nexium when an appeals court ruled that a new drug from Hanmi Pharmaceuticals did not infringe on Nexium patents.

  • WASHINGTON, Dec 19- The drug company AstraZeneca PLC lost a bid on Thursday to defend its widely used heartburn drug Nexium when an appeals court ruled that a new drug from Hanmi Pharmaceuticals did not infringe on Nexium patents.

  • Early movers: TGT, FB, ORCL, DRI & more Thursday, 19 Dec 2013 | 9:12 AM ET

    Companies are making headlines before the bell Thursday.

  • AstraZeneca shares up on Bristol-Myers diabetes deal Thursday, 19 Dec 2013 | 6:36 AM ET

    AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture in a deal worth $4.1 billion.

  • LONDON, Dec 19- AstraZeneca has agreed to buy Bristol-Myers Squibb's stake in the companies' diabetes joint venture for up to $4.1 billion in a deal that will help return the group to growth, sending its shares to an new high.

  • FDA approves another GSK, Theravance lung drug Wednesday, 18 Dec 2013 | 12:05 PM ET

    Dec 18- The U.S. Food and Drug Administration approved GlaxoSmithKline Plc's new lung drug for treatment of chronic obstructive pulmonary disease, commonly known as smoker's lung.

  • LONDON, Dec 17- GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff- a first for an industry battling scandals over its sales practices, and a challenge for its peers to follow suit.

  • LONDON, Dec 17- GlaxoSmithKline will stop paying doctors for promoting its drugs and scrap prescription targets for its marketing staff- a first for an industry battling scandals over its sales practices, and a challenge for its peers to follow suit.

  • Pharma: 'Key patents' end soon     Tuesday, 17 Dec 2013 | 5:20 AM ET

    James Wade, senior analyst at Datamonitor Healthcare, talks about the pharmaceuticals industry which faces a "big patent cliff" at the moment, and discusses the outlook for next year.

  • LONDON, Dec 17- GlaxoSmithKline will stop paying doctors to promote its products at events and remove individual sales targets for its marketing staff in a first for the drugs industry looking to recover from scandals over improper sales practices.

Most Popular Video

Sunday, 20 Apr 2014 | 11:08 PM ET

Kelvin Tay, MD & Regional CIO for Southern APAC at UBS Wealth Management, expects U.S. firms to report 8 percent growth for 2014, but warns of risks from the recent winter freeze.

Sunday, 20 Apr 2014 | 10:47 PM ET

David Forrester, Senior Vice President, G10 FX Strategy at Macquarie, expects the Bank of Japan to unleash more stimulus ahead, which will spur further yen weakness.

Sunday, 20 Apr 2014 | 10:39 PM ET

James Chao, Director, Asia Pacific at IHS Automotive Consulting, addresses concerns surrounding the quality of vehicles made in China.